



0350

#7

PATENT

Customer No. 22,852

Attorney Docket No. 2481.1761-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )

Birgit JORDAN et al. )

Application No.: 09/989,188 )

Filed: November 21, 2001 )

For: PROCESS FOR SCREENING CHEMICAL )  
COMPOUNDS FOR MODULATING THE )  
INTERACTION OF AN EVH1 DOMAIN OR A )  
PROTEIN HAVING AN EVH1 DOMAIN WITH )  
AN EVH1 BINDING DOMAIN OR A PROTEIN )  
HAVING AN EVH1 BINDING DOMAIN, AND )  
A PROCESS FOR DETECTING SAID )  
INTERACTION )

Group Art Unit: To Be  
Assigned

Examiner: To Be Assigned

Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are enclosed. A Dialog abstract in English of the non-English document WO 01/96594 is enclosed. It is also noted that WO 01/96594 contains an Abstract in English. Applicants respectfully request that the Examiner

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 24, 2003

By:   
Carol R. Einaudi  
Reg. No. 32,220

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

## INFORMATION DISCLOSURE CITATION

Atty. Docket No. 2481.1761-00	Appln. No. 09/989,188
Applicant Birgit JORDAN et al.	
Filing Date November 21, 2001	Group: To Be Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
	WO 01/74858	10-11-01	PCT			English Document	
	WO 01/96594	12-20-01	PCT			English Abstract	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Bader et al., A cGMP-dependent Protein Kinase Assay for High Throughput Screening Based on Time-Resolved Fluorescence Resonance Energy Transfer, <i>J. Biomol. Screen.</i> 6:255-64 (2001).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce